The UltiSynq defibrillation lead from Abbott gives clinicians a new option for left bundle branch area pacing. The device has also received CE mark approval.
The FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.
This represents the first randomized trial focused on treating moderate aortic stenosis with Medtronic's self-expanding, supra-annular Evolut platform.
Laza Medical, a California-based medtech company, is developing advanced technologies for the cath lab. GE HealthCare also participated in a previous financing round in 2023.
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
